Page last updated: 2024-10-26

emodin and Breast Neoplasms

emodin has been researched along with Breast Neoplasms in 41 studies

Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.
emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.

Breast Neoplasms: Tumors or cancer of the human BREAST.

Research Excerpts

ExcerptRelevanceReference
"Phytoestrogens have been investigated for their potential anti-tumorigenic effects in various cancers including breast cancer."8.12Identification of Potential Therapeutic Genes and Pathways in Phytoestrogen Emodin Treated Breast Cancer Cell Lines via Network Biology Approaches. ( Guray, NT; Sakalli-Tecim, E; Uyar-Arpaci, P, 2022)
"Low dose Emodin potentiates 5-FU-induced apoptosis of breast cancer cells, in association with inhibition of NRARP, resulting in cellular senescence."7.88Low dose Emodin induces tumor senescence for boosting breast cancer chemotherapy via silencing NRARP. ( He, A; Liu, N; Qin, G; Yang, C; Zhang, M; Zheng, X; Zu, C, 2018)
" In this study, we tested the ability of emodin, a Chinese herb-derived compound, to inhibit breast cancer growth in mice and examined the underlying mechanisms."7.83Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages. ( Fan, D; Hodge, J; Iwanowycz, S; Wang, J; Wang, Y; Yu, F, 2016)
"The aim of the present study was to investigate the involvement of emodin on the growth of human breast cancer MCF-7 and MDA-MB-231 cells and the estrogen (E2) signal pathway in vitro."7.80Emodin inhibits breast cancer cell proliferation through the ERα-MAPK/Akt-cyclin D1/Bcl-2 signaling pathway. ( Sui, JQ; Xie, KP; Xie, MJ; Zou, W, 2014)
" In this study, the drug delivery and efficacy of silk fibroin coated liposomes (SF-ELP), encapsulating a receptor tyrosine kinase inhibitor, emodin, on Her2/neu over-expressing breast cancer cells, was investigated."7.74Silk fibroin mediated delivery of liposomal emodin to breast cancer cells. ( Cheema, SK; Gobin, AS; Lopez-Berestein, G; Mathur, AB; Newman, RA; Rhea, R, 2007)
"The amplification and overexpression of the HER-2/neu proto-oncogene, which encodes the tyrosine kinase receptor p185neu, have been observed frequently in tumors from human breast cancer patients and are correlated with poor prognosis."7.69Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. ( Bacus, SS; Chang, CJ; Hung, MC; Zhang, L, 1995)
"Breast cancer has been among the most prominent cancers with high mortality."5.91Systems biology based miRNA-mRNA expression pattern analysis of Emodin in breast cancer cell lines. ( Gur-Dedeoglu, B; Guray, NT; Sakalli-Tecim, E, 2023)
"Elevated SIK3 expressions in breast cancer cells are shown to contribute to tumorigenesis; however, the underlying mechanism remains to be elucidated."5.56Berberine and Emodin abrogates breast cancer growth and facilitates apoptosis through inactivation of SIK3-induced mTOR and Akt signaling pathway. ( Kothandan, G; Manoharan, R; Ponnusamy, L, 2020)
"Dual dosage enhanced apoptosis through ROS generation, anti- migratory effect by targeting FAK &Integrins, displaying effective stemness control by assessing regulatory proteins- Oct4, Sox2, Nanog, ALDH1/2."5.56Combinatorial therapy of Thymoquinone and Emodin synergistically enhances apoptosis, attenuates cell migration and reduces stemness efficiently in breast cancer. ( Adhikary, A; Basu, A; Bhattacharjee, M; Das, S; Ghosh, A; Ghosh, S; Sarker, S; Upadhyay, P, 2020)
"Treatment of HER-2-overexpressing breast cancer cells with AE reduced tumor initiation, cell migration, and cell invasion."5.43Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells. ( Ho, CT; Hung, CM; Kao, JY; Lin, YC; Ma, JW; Way, TD, 2016)
"Aloe-emodin (AE) has been found to be an anti-tumor agent in many studies, and has also been demonstrated as a photosensitizer, in the recent years."5.43Exploring a Novel Target Treatment on Breast Cancer: Aloe-emodin Mediated Photodynamic Therapy Induced Cell Apoptosis and Inhibited Cell Metastasis. ( Bai, DQ; Chen, Q; Li, KT; Tian, S; Yu, LH; Yu, TH; Zhu, J, 2016)
"Emodin (EMD) is an anthraquinone derivative extracted from the root and rhizome of Rheum palmatum L."5.42The anthraquinone derivative Emodin inhibits angiogenesis and metastasis through downregulating Runx2 activity in breast cancer. ( Chen, B; Fu, J; Ke, X; Liu, T; Liu, Z; Lu, H; Ma, J; Wang, S, 2015)
"In the present study, we used breast cancer MDA-MB-231 cells and a mouse xenograft model to demonstrate the effect of emodin on the migration, invasion and metastasis of human breast cancer MDA-MB-231 cells and the related mechanisms."5.42Inhibitory effect of emodin on migration, invasion and metastasis of human breast cancer MDA-MB-231 cells in vitro and in vivo. ( Chen, Q; Lu, Y; Su, S; Sun, Y; Wang, X; Zhang, H; Zhao, M; Zhou, Q, 2015)
"Breast cancer is the leading cause of death in female cancer patients due to the lack of effective treatment for metastasis."5.40Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs. ( Fan, D; Hu, J; Iwanowycz, S; Jia, X; Saaoud, F; Wang, J; Wang, Q; Wang, Y; Yu, F, 2014)
"Emodin is an active anthraquinone that has been reported to have diverse biological effects."5.39Emodin induces cytotoxic effect in human breast carcinoma MCF-7 cell through modulating the expression of apoptosis-related genes. ( Chan, RY; Chan, SW; Li, WY; Yu, PH, 2013)
"Emodin is an active component isolated from the root and rhizome of Rheum palmatum that has been widely used in traditional Chinese medicine for the treatment of various diseases."5.39Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. ( Gao, J; Guo, J; Kong, Y; Li, L; Li, W; Liu, P; Shi, H; Tang, H; Wei, W; Wu, M; Xie, X; Yang, L, 2013)
"When emodin was added to the cell culture at the concentration of 10 μg/ml, the drug resistance was reduced from 21 folds to 2."5.38Emodin affects ERCC1 expression in breast cancer cells. ( Chow, LW; Fu, JM; Huang, L; Loo, WT; Ng, EL; Shi, J; Xie, JS; Yip, AY; Zhou, J, 2012)
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."4.21 ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)
"Phytoestrogens have been investigated for their potential anti-tumorigenic effects in various cancers including breast cancer."4.12Identification of Potential Therapeutic Genes and Pathways in Phytoestrogen Emodin Treated Breast Cancer Cell Lines via Network Biology Approaches. ( Guray, NT; Sakalli-Tecim, E; Uyar-Arpaci, P, 2022)
"Low dose Emodin potentiates 5-FU-induced apoptosis of breast cancer cells, in association with inhibition of NRARP, resulting in cellular senescence."3.88Low dose Emodin induces tumor senescence for boosting breast cancer chemotherapy via silencing NRARP. ( He, A; Liu, N; Qin, G; Yang, C; Zhang, M; Zheng, X; Zu, C, 2018)
" In this study, we tested the ability of emodin, a Chinese herb-derived compound, to inhibit breast cancer growth in mice and examined the underlying mechanisms."3.83Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages. ( Fan, D; Hodge, J; Iwanowycz, S; Wang, J; Wang, Y; Yu, F, 2016)
"The aim of the present study was to investigate the involvement of emodin on the growth of human breast cancer MCF-7 and MDA-MB-231 cells and the estrogen (E2) signal pathway in vitro."3.80Emodin inhibits breast cancer cell proliferation through the ERα-MAPK/Akt-cyclin D1/Bcl-2 signaling pathway. ( Sui, JQ; Xie, KP; Xie, MJ; Zou, W, 2014)
" The scaffold-emodin nanoparticle composites were fabricated and characterized for drug entrapment and release, mechanical strength, and efficacy against GILM2 breast cancer cells in vitro and in vivo in a rat tumor model."3.77Repair and reconstruction of a resected tumor defect using a composite of tissue flap-nanotherapeutic-silk fibroin and chitosan scaffold. ( Aseh, A; Chang, D; Choi, B; Gupta, V; Mathur, AB; Mildred, L; Mun, GH; Patel, A; Price, JE; Robb, G; Zhang, Q, 2011)
"An apoptosis-associated cDNA microarray comprised of 458 known genes, namely, death receptors, calpains, death kinases, granzymes, DNA fragmentation proteins, caspases and Bcl-2 family, was used to determine the impact of emodin in breast cancer BCap-37 cells."3.75Effects of emodin on the gene expression profiling of human breast carcinoma cells. ( Chen, G; Huang, Z; Shi, P, 2009)
" In this study, the drug delivery and efficacy of silk fibroin coated liposomes (SF-ELP), encapsulating a receptor tyrosine kinase inhibitor, emodin, on Her2/neu over-expressing breast cancer cells, was investigated."3.74Silk fibroin mediated delivery of liposomal emodin to breast cancer cells. ( Cheema, SK; Gobin, AS; Lopez-Berestein, G; Mathur, AB; Newman, RA; Rhea, R, 2007)
"The amplification and overexpression of the HER-2/neu proto-oncogene, which encodes the tyrosine kinase receptor p185neu, have been observed frequently in tumors from human breast cancer patients and are correlated with poor prognosis."3.69Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. ( Bacus, SS; Chang, CJ; Hung, MC; Zhang, L, 1995)
"Advanced breast cancer is prone to metastasis, and there is currently no drug to cure metastatic breast cancer."2.72P2X7 receptor: a critical regulator and potential target for breast cancer. ( Li, Q; Peng, X; Song, W; Zhao, R; Zhu, X, 2021)
"Breast cancer has been among the most prominent cancers with high mortality."1.91Systems biology based miRNA-mRNA expression pattern analysis of Emodin in breast cancer cell lines. ( Gur-Dedeoglu, B; Guray, NT; Sakalli-Tecim, E, 2023)
"Breast cancer is one of the most diffuse cancers in the world and despite the availability of the different drugs employed against it, the need for new and particularly more specific molecules is ever growing."1.72Peptide-Mediated Targeted Delivery of Aloe-Emodin as Anticancer Drug. ( Calcabrini, A; Cecchetti, S; Colone, M; Dupuis, ML; Gori, A; Serra, S; Spadaro, F; Stringaro, A; Vitali, A, 2022)
"Human breast cancer cell MCF-7 was treated with 5-400 µM Phy for 24 h, MCF-7-xenografted BALB/c nude mice and immunosuppressive mice model induced by cyclophosphamide were intraperitoneally injected with 0."1.62The anti-breast cancer property of physcion via oxidative stress-mediated mitochondrial apoptosis and immune response. ( Dong, R; Jia, D; Meng, Z; Wang, L; Wang, Y; Zhang, L; Zhou, T, 2021)
"Dual dosage enhanced apoptosis through ROS generation, anti- migratory effect by targeting FAK &Integrins, displaying effective stemness control by assessing regulatory proteins- Oct4, Sox2, Nanog, ALDH1/2."1.56Combinatorial therapy of Thymoquinone and Emodin synergistically enhances apoptosis, attenuates cell migration and reduces stemness efficiently in breast cancer. ( Adhikary, A; Basu, A; Bhattacharjee, M; Das, S; Ghosh, A; Ghosh, S; Sarker, S; Upadhyay, P, 2020)
"Elevated SIK3 expressions in breast cancer cells are shown to contribute to tumorigenesis; however, the underlying mechanism remains to be elucidated."1.56Berberine and Emodin abrogates breast cancer growth and facilitates apoptosis through inactivation of SIK3-induced mTOR and Akt signaling pathway. ( Kothandan, G; Manoharan, R; Ponnusamy, L, 2020)
"Given the aggressive properties of breast cancer, the current study suggests that PG can serve as a safe therapeutic agent for suppressing breast cancer metastasis, although additional data is necessitated."1.46Physcion 8-O-β-glucopyranoside suppresses the metastasis of breast cancer in vitro and in vivo by modulating DNMT1. ( Chen, X; Fan, D; Guo, H; Li, F, 2017)
"Aloe-emodin (AE) has been found to be an anti-tumor agent in many studies, and has also been demonstrated as a photosensitizer, in the recent years."1.43Exploring a Novel Target Treatment on Breast Cancer: Aloe-emodin Mediated Photodynamic Therapy Induced Cell Apoptosis and Inhibited Cell Metastasis. ( Bai, DQ; Chen, Q; Li, KT; Tian, S; Yu, LH; Yu, TH; Zhu, J, 2016)
"Treatment of HER-2-overexpressing breast cancer cells with AE reduced tumor initiation, cell migration, and cell invasion."1.43Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells. ( Ho, CT; Hung, CM; Kao, JY; Lin, YC; Ma, JW; Way, TD, 2016)
"In the present study, we used breast cancer MDA-MB-231 cells and a mouse xenograft model to demonstrate the effect of emodin on the migration, invasion and metastasis of human breast cancer MDA-MB-231 cells and the related mechanisms."1.42Inhibitory effect of emodin on migration, invasion and metastasis of human breast cancer MDA-MB-231 cells in vitro and in vivo. ( Chen, Q; Lu, Y; Su, S; Sun, Y; Wang, X; Zhang, H; Zhao, M; Zhou, Q, 2015)
"Emodin (EMD) is an anthraquinone derivative extracted from the root and rhizome of Rheum palmatum L."1.42The anthraquinone derivative Emodin inhibits angiogenesis and metastasis through downregulating Runx2 activity in breast cancer. ( Chen, B; Fu, J; Ke, X; Liu, T; Liu, Z; Lu, H; Ma, J; Wang, S, 2015)
"Breast cancer is the leading cause of death in female cancer patients due to the lack of effective treatment for metastasis."1.40Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs. ( Fan, D; Hu, J; Iwanowycz, S; Jia, X; Saaoud, F; Wang, J; Wang, Q; Wang, Y; Yu, F, 2014)
"Emodin is an active component isolated from the root and rhizome of Rheum palmatum that has been widely used in traditional Chinese medicine for the treatment of various diseases."1.39Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. ( Gao, J; Guo, J; Kong, Y; Li, L; Li, W; Liu, P; Shi, H; Tang, H; Wei, W; Wu, M; Xie, X; Yang, L, 2013)
"Emodin is an active anthraquinone that has been reported to have diverse biological effects."1.39Emodin induces cytotoxic effect in human breast carcinoma MCF-7 cell through modulating the expression of apoptosis-related genes. ( Chan, RY; Chan, SW; Li, WY; Yu, PH, 2013)
"When emodin was added to the cell culture at the concentration of 10 μg/ml, the drug resistance was reduced from 21 folds to 2."1.38Emodin affects ERCC1 expression in breast cancer cells. ( Chow, LW; Fu, JM; Huang, L; Loo, WT; Ng, EL; Shi, J; Xie, JS; Yip, AY; Zhou, J, 2012)

Research

Studies (41)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (4.88)18.2507
2000's6 (14.63)29.6817
2010's19 (46.34)24.3611
2020's14 (34.15)2.80

Authors

AuthorsStudies
Jabor Gozzi, G1
Bouaziz, Z1
Winter, E1
Daflon-Yunes, N1
Aichele, D1
Nacereddine, A1
Marminon, C1
Valdameri, G1
Zeinyeh, W1
Bollacke, A1
Guillon, J1
Lacoudre, A1
Pinaud, N1
Cadena, SM1
Jose, J1
Le Borgne, M1
Di Pietro, A1
Cheng, K1
Zhou, J3
Zhao, Y3
Chen, Y5
Ming, L1
Huang, D2
Yang, R1
Lin, Z1
Chen, D1
Stringaro, A1
Serra, S1
Gori, A1
Calcabrini, A1
Colone, M1
Dupuis, ML1
Spadaro, F1
Cecchetti, S1
Vitali, A1
Sakalli-Tecim, E2
Gur-Dedeoglu, B1
Guray, NT2
Okon, E1
Gaweł-Bęben, K1
Jarzab, A1
Koch, W1
Kukula-Koch, W1
Wawruszak, A1
Fu, M1
Tang, W1
Liu, JJ1
Gong, XQ1
Kong, L2
Yao, XM1
Jing, M1
Cai, FY1
Li, XT1
Ju, RJ1
Zou, G1
Zhang, X2
Wang, L6
Li, X5
Xie, T1
Zhao, J1
Yan, J1
Ye, H1
Jiao, S1
Xiang, R1
Shi, Y1
Ponnusamy, L1
Kothandan, G1
Manoharan, R1
Bhattacharjee, M1
Upadhyay, P1
Sarker, S1
Basu, A1
Das, S1
Ghosh, A1
Ghosh, S1
Adhikary, A1
Nese, M1
Riboli, G1
Brighetti, G1
Sassi, V1
Camela, E1
Caselli, G1
Sassaroli, S1
Borlimi, R1
Aucoin, M1
Cooley, K1
Saunders, PR1
Carè, J1
Anheyer, D1
Medina, DN1
Cardozo, V1
Remy, D1
Hannan, N1
Garber, A1
Velayos, M1
Muñoz-Serrano, AJ1
Estefanía-Fernández, K1
Sarmiento Caldas, MC1
Moratilla Lapeña, L1
López-Santamaría, M1
López-Gutiérrez, JC1
Li, J2
Zhang, J1
Shen, S1
Zhang, B2
Yu, WW1
Toyoda, H1
Huang, DQ1
Le, MH1
Nguyen, MH1
Huang, R1
Zhu, L1
Wang, J9
Xue, L1
Liu, L2
Yan, X2
Huang, S1
Li, Y6
Xu, T1
Li, C2
Ji, F1
Ming, F1
Cheng, J1
Wang, Y7
Zhao, H1
Hong, S1
Chen, K2
Zhao, XA1
Zou, L1
Sang, D1
Shao, H1
Guan, X1
Chen, X3
Wei, J1
Zhu, C1
Wu, C1
Moore, HB1
Barrett, CD1
Moore, EE1
Jhunjhunwala, R1
McIntyre, RC1
Moore, PK1
Hajizadeh, N1
Talmor, DS1
Sauaia, A1
Yaffe, MB1
Liu, C3
Lin, Y1
Dong, Y1
Wu, Y1
Bao, Y1
Yan, H2
Ma, J2
Fernández-Cuadros, ME1
Albaladejo-Florín, MJ1
Álava-Rabasa, S1
Usandizaga-Elio, I1
Martinez-Quintanilla Jimenez, D1
Peña-Lora, D1
Neira-Borrajo, I1
López-Muñoz, MJ1
Rodríguez-de-Cía, J1
Pérez-Moro, OS1
Abdallah, M1
Alsaleh, H1
Baradwan, A1
Alfawares, R1
Alobaid, A1
Rasheed, A1
Soliman, I1
Wendel Garcia, PD1
Fumeaux, T1
Guerci, P1
Heuberger, DM1
Montomoli, J2
Roche-Campo, F1
Schuepbach, RA1
Hilty, MP1
Poloni, TE1
Carlos, AF1
Cairati, M1
Cutaia, C1
Medici, V1
Marelli, E1
Ferrari, D1
Galli, A1
Bognetti, P1
Davin, A1
Cirrincione, A1
Ceretti, A1
Cereda, C1
Ceroni, M1
Tronconi, L1
Vitali, S1
Guaita, A1
Leeds, JS1
Raviprakash, V1
Jacques, T1
Scanlon, N1
Cundall, J1
Leeds, CM1
Riva, A1
Gray, EH1
Azarian, S1
Zamalloa, A1
McPhail, MJW1
Vincent, RP1
Williams, R1
Chokshi, S1
Patel, VC1
Edwards, LA1
Alqarawi, W1
Birnie, DH1
Golian, M1
Nair, GM1
Nery, PB1
Klein, A1
Davis, DR1
Sadek, MM1
Neilipovitz, D1
Johnson, CB1
Green, MS1
Redpath, C1
Miller, DC1
Beamer, P1
Billheimer, D1
Subbian, V1
Sorooshian, A1
Campbell, BS1
Mosier, JM1
Novaretti, JV1
Astur, DC1
Cavalcante, ELB1
Kaleka, CC1
Amaro, JT1
Cohen, M1
Huang, W1
Li, T1
Ling, Y1
Qian, ZP1
Zhang, YY1
Xu, SB1
Liu, XH1
Xia, L1
Yang, Y4
Lu, SH1
Lu, HZ1
Zhang, R2
Ma, JX1
Tang, S1
Li, CM1
Wan, J1
Wang, JF1
Ma, JQ1
Luo, JJ1
Chen, HY2
Mi, SL1
Chen, SY1
Su, YG1
Ge, JB1
Milheiro, SA1
Gonçalves, J1
Lopes, RMRM1
Madureira, M1
Lobo, L1
Lopes, A1
Nogueira, F1
Fontinha, D1
Prudêncio, M1
M Piedade, MF1
Pinto, SN1
Florindo, PR1
Moreira, R1
Castillo-Lora, J1
Delley, MF1
Laga, SM1
Mayer, JM1
Sutjarit, N1
Thongon, N1
Weerachayaphorn, J1
Piyachaturawat, P1
Suksamrarn, A1
Suksen, K1
Papachristou, DJ1
Blair, HC1
Hu, Y2
Shen, P1
Zeng, N1
Yan, D1
Cui, L1
Yang, K2
Zhai, C1
Yang, M1
Lao, X1
Sun, J1
Ma, N1
Wang, S3
Ye, W1
Guo, P1
Rahimi, S1
Singh, MP1
Gupta, J1
Nakanishi, I1
Ohkubo, K1
Shoji, Y1
Fujitaka, Y1
Shimoda, K1
Matsumoto, KI1
Fukuhara, K1
Hamada, H1
van der Boom, T1
Gruppen, EG1
Lefrandt, JD1
Connelly, MA1
Links, TP1
Dullaart, RPF1
Berry, JD1
Bedlack, R1
Mathews, D1
Agnese, W1
Apple, S1
Meloncelli, S1
Divizia, M1
Germani, G1
Adefegha, SA1
Bottari, NB1
Leal, DB1
de Andrade, CM1
Schetinger, MR1
Martínez-Velasco, A1
Perez-Ortiz, AC1
Antonio-Aguirre, B1
Martínez-Villaseñor, L1
Lira-Romero, E1
Palacio-Pastrana, C1
Zenteno, JC1
Ramirez, I1
Zepeda-Palacio, C1
Mendoza-Velásquez, C1
Camacho-Ordóñez, A1
Ortiz Bibriesca, DM1
Estrada-Mena, FJ1
Martin, BL1
Thompson, LC1
Kim, YH2
Snow, SJ1
Schladweiler, MC1
Phillips, P1
Harmon, M1
King, C1
Richards, J1
George, I1
Haykal-Coates, N1
Gilmour, MI1
Kodavanti, UP1
Hazari, MS1
Farraj, AK1
Shen, Z1
Zou, Y1
Gao, K1
Lazar, S1
Wurtzel, JGT1
Ma, P1
Goldfinger, LE1
Vukelic, M1
Laloo, A1
Kyttaris, VC1
Chen, R2
Chen, J2
Xun, J1
Hu, Z1
Huang, Q2
Steinhart, C1
Shen, Y1
Lu, H2
Mansuri, A1
Lokhande, K1
Kore, S1
Gaikwad, S1
Nawani, N1
Swamy, KV1
Junnarkar, M1
Pawar, S1
Shaheen, MY1
Basudan, AM1
Niazy, AA1
van den Beucken, JJJP1
Jansen, JA1
Alghamdi, HS1
Gao, Q2
Guo, X1
Cao, Y1
Jia, X2
Xu, S1
Lu, C2
Zhu, H2
Melku, M1
Abebe, G1
Teketel, A1
Asrie, F1
Yalew, A1
Biadgo, B1
Kassa, E1
Damtie, D1
Anlay, DZ1
Ahmed, MFE1
Ramadan, H1
Seinige, D1
Kehrenberg, C1
Abd El-Wahab, A1
Volkmann, N1
Kemper, N1
Schulz, J1
Hu, MY1
Wu, YN1
McEvoy, MP1
Wang, YF1
Cong, WL1
Liu, LP1
Li, XX1
Zhou, CL1
Chen, WM1
Wei, KL1
Tung, SY1
Shen, CH1
Chang, TS1
Yen, CW1
Hsieh, YY1
Chiu, WN1
Hu, JH1
Lu, SN1
Hung, CH1
Alakavuklar, MA1
Fuqua, C1
Luo, KL1
Underwood, RS1
Greenwald, I1
Elashiry, MM1
Elashiry, M1
Zeitoun, R1
Elsayed, R1
Tian, F1
Saber, SE1
Elashry, SH1
Tay, FR1
Cutler, CW1
O'Dowd, A1
Maciel, M1
Poole, ST1
Jobling, MG1
Rollenhagen, JE1
Woods, CM1
Sincock, SA1
McVeigh, AL1
Gregory, MJ1
Maves, RC1
Prouty, MG1
Holmes, RK1
Savarino, SJ1
Mor, MK1
Palevsky, PM1
Kaufman, JS1
Thiessen Philbrook, H1
Weisbord, SD1
Parikh, CR1
John, CM1
Phillips, NJ1
Jarvis, GA1
Zhu, Y1
Kilburn, S1
Kapoor, M1
Chaturvedi, S1
Shaw, KJ1
Chaturvedi, V1
Kong, X1
Zhang, T1
Xiao, H1
Feng, X1
Tu, H1
Feng, J1
Sabet, M1
Tarazi, Z1
Griffith, DC1
Nguyen, F1
Guan, P1
Guerrero, DT1
Kolla, V1
Naraparaju, K1
Perry, LM1
Soberman, D1
Pressly, BB1
Alferiev, IS1
Chorny, M1
Brodeur, GM1
Gao, X2
Cheng, YH1
Enten, GA1
DeSantis, AJ1
Gaponenko, V1
Majetschak, M1
Kim, DY1
Choi, MJ1
Ko, TK1
Lee, NH1
Kim, OH1
Cheon, HG1
Cai, H1
Yip, V1
Lee, MV1
Wong, S1
Saad, O1
Ma, S1
Ljumanovic, N1
Khojasteh, SC1
Kamath, AV1
Shen, BQ1
Cuypers, ML1
Chanteux, H1
Gillent, E1
Bonnaillie, P1
Saunders, K1
Beckers, C1
Delatour, C1
Dell'Aiera, S1
Ungell, AL1
Nicolaï, J1
Knapp, AK1
Chen, A1
Griffin-Nolan, RJ1
Baur, LE1
Carroll, CJW1
Gray, JE1
Hoffman, AM1
Post, AK1
Slette, IJ1
Collins, SL1
Luo, Y1
Smith, MD1
Temitayo, GI1
Olawande, B1
Emmanuel, YO1
Timothy, AT1
Kehinde, O1
Susan, LF1
Ezra, L1
Joseph, OO1
Lev, S1
Desmarini, D1
Liuwantara, D1
Sorrell, TC1
Hawthorne, WJ1
Djordjevic, JT1
Verso, MG1
Costantino, C1
Marrella, A1
Immordino, P1
Vitale, F1
Amodio, E1
Wang, YD1
Yao, WL1
Xin, ZM1
Han, TT1
Wang, ZG1
Chen, L1
Cai, C1
Zhang, Y4
Ba, D1
Wen, S1
Tian, Q1
Lv, W1
Cheng, G2
Li, N1
Yue, XY1
Chu, WJ1
Chen, Q3
Choi, ES1
Zhao, X3
Zhou, HD1
Sun, XF1
Sharma, S2
Chhoker, S1
Xie, C1
Ong, EWY1
Tan, ZK1
Evans, S1
Weinheimer, CJ1
Kovacs, A1
Williams, JW1
Randolph, GJ1
Jiang, W1
Barger, PM1
Mann, DL1
Liu, J2
Huang, Y1
Yu, X1
Feng, B1
Liu, D1
Zhao, B1
Mendes, GC1
Yuan, P1
Ge, D1
Wang, WM1
Fontes, EPB1
Li, P1
Shan, L1
He, P1
Katoh, T1
Sengoku, T1
Hirata, K1
Ogata, K1
Suga, H1
Shun, C1
Yong-Yi, J1
Mei-Li, C1
Shi-Li, L1
Jian-Bo, Z1
Dan-Li, W1
Zhi-Min, G1
Ibrahim, AM1
Zakhary, SY1
Amin, SAW1
Ugurlu, M1
Fornari, VJ1
Hartmann, MSM1
Vanni, JR1
Rodriguez, R1
Langaro, MC1
Pelepenko, LE1
Zaia, AA1
Nakanjako, D1
Zalwango, F1
Wairagala, P1
Luboga, F1
Andia Biraro, I1
Bukirwa, VD1
Mboowa, MG1
Cose, S1
Seeley, J1
Elliott, A1
Zhao, G1
Sun, P1
Hao, S1
Wang, X2
Qu, G1
Xing, Y1
Xu, X1
Maierhofer, M1
Rieger, V1
Mayr, T1
Liu, Y2
Zhang, Q2
Bigliardi, AP1
Fernandes, CLF1
Pinto, EA1
Dos Santos, M1
Garcia, EM1
Baisch, PRM1
Soares, MCF1
Muccillo-Baisch, AL1
da Silva Júnior, FMR1
Yu, W1
Ju, C1
Wang, K1
Zheng, Z2
Liu, H1
Gao, Y1
Martínez-Navarro, EM1
Cebrián-Tarancón, C1
Moratalla-López, N1
Lorenzo, C1
Alonso, GL1
Salinas, RM1
Bermúdez de Castro, JM1
Modesto-Mata, M1
Martín-Francés, L1
García-Campos, C1
Martínez de Pinillos, M1
Martinón-Torres, M1
Hasani, M1
Wu, F2
Warriner, K1
Kurz, M1
Gretzke, D1
Hörlein, R1
Turpault, S1
Atzrodt, J1
Derdau, V1
Yao, Y1
Ou, X1
Zhao, S1
Tian, B1
Jin, S1
Jiang, Z1
Zhou, Z1
Liu, M2
Jiang, GD1
Mou, LH1
Chen, JJ1
Li, ZY1
He, SG1
Reale, E1
Fustinoni, S1
Mercadante, R1
Polledri, E1
Hopf, NB1
Grant, PC1
Levy, K1
Lattimer, TA1
Depner, RM1
Kerr, CW1
Sato, J1
Merenda, MEZ1
Uemoto, AT1
Dos Santos, MP1
Barion, MRL1
Carciofi, AC1
de Paula Dorigam, JC1
Ribeiro, LB1
Vasconcellos, RS1
Waller, SB1
Peter, CM1
Hoffmann, JF1
Cleff, MB1
Faria de, RO1
Zani, JL1
Martins, BA1
Sande, D1
Solares, MD1
Takahashi, JA1
Yang, S2
Jia, Y1
Yin, C1
Zhao, R2
Ojha, M1
Wu, B1
Deepa, M1
Mo, J1
Au, DW1
Wan, MT1
Shi, J2
Zhang, G1
Winkler, C1
Kong, RY1
Seemann, F1
Bianco, M1
Calvano, CD1
Ventura, G1
Bianco, G1
Losito, I1
Cataldi, TRI1
Angiolella, L1
Staudt, A1
Duarte, PF1
Amaral, BPD1
Peixoto Andrade, BCO1
Simas, NK1
Correa Ramos Leal, I1
Sangenito, LS1
Santos, ALSD1
de Oliveira, D1
Junges, A1
Cansian, RL1
Paroul, N1
Siu, J1
Klingler, L1
Hung, CT1
Jeong, SH1
Smith, S1
Tingle, MD1
Wagner Mackenzie, B1
Biswas, K1
Douglas, RG1
Oza, AM1
Lorusso, D1
Aghajanian, C1
Oaknin, A1
Dean, A1
Colombo, N1
Weberpals, JI1
Clamp, AR1
Scambia, G1
Leary, A1
Holloway, RW1
Gancedo, MA1
Fong, PC1
Goh, JC1
O'Malley, DM1
Armstrong, DK1
Banerjee, S1
García-Donas, J1
Swisher, EM1
Cella, D1
Meunier, J1
Goble, S1
Cameron, T1
Maloney, L1
Mörk, AC1
Bedel, J1
Ledermann, JA1
Coleman, RL1
Vlek, SL1
Burm, R1
Govers, TM1
Vleugels, MPH1
Tuynman, JB1
Mijatovic, V1
Leicht, AS1
Connor, J1
Conduit, N1
Vaquera, A1
Gómez, MA1
McKay, JA1
Church, AL1
Rubin, N1
Emory, TH1
Hoven, NF1
Kuehn-Hajder, JE1
Nelson, MT1
Ramanna, S1
Auerbach, EJ1
Moeller, S1
Bolan, PJ1
Fox, NP1
Leonard, M1
Sjerps, MJ1
Chang, EF1
Hyun, S1
Saejio, A1
Shanmugam, S1
Liu, X1
Sun, M1
Bai, Z1
Jaque-Fernandez, F1
Beaulant, A1
Berthier, C1
Monteiro, L1
Allard, B1
Casas, M1
Rieusset, J1
Jacquemond, V1
Góngora-García, OR1
Aca-Aca, G1
Baz-Rodríguez, SA1
Monte, A1
Maganaris, C1
Baltzopoulos, V1
Zamparo, P1
Wang, Z2
Hou, Y1
Cai, L1
Tu, YJ1
Tan, B1
Jiang, L1
Wu, ZH1
Yu, HJ1
Li, XQ1
Yang, AD1
Titze, IR1
Palaparthi, A1
Mau, T1
González, MA1
Goiri, F1
Barandika, JF1
García-Pérez, AL1
Jatt, LP1
Gandhi, MM1
Guo, R1
Sukhija-Cohen, A1
Bhattacharya, D1
Tseng, CH1
Chew, KW1
Onwumere, J1
Pia Tek, J1
Budnyak, T1
Budnyk, S1
Karim, Z1
Thersleff, T1
Kuśtrowski, P1
Mathew, AP1
Slabon, A1
Guo, M1
Zhao, T1
Xing, Z1
Qiu, Y1
Pan, K1
Li, Z2
Zhou, W1
Ghassemi Tabrizi, S1
Arbuznikov, AV1
Jiménez-Hoyos, CA1
Kaupp, M1
Lin, MH2
Bulman, DM1
Remucal, CK1
Chaplin, BP1
Laguerre, A1
George, LA1
Gall, ET1
Emerson, MS1
Wang, H3
Maginn, EJ1
Margulis, CJ1
Li, H2
Feng, W1
Kang, X2
Yan, S1
Chao, M1
Mo, S1
Sun, W1
Lu, Y3
Chen, C1
Stevens, DM1
Adiseshaiah, P1
Dasa, SSK1
Potter, TM1
Skoczen, SL1
Snapp, KS1
Cedrone, E1
Patel, N1
Busman-Sahay, K1
Rosen, EP1
Sykes, C1
Cottrell, M1
Dobrovolskaia, MA1
Estes, JD1
Kashuba, ADM1
Stern, ST1
Özütemiz, C1
Neil, EC1
Tanwar, M1
Rubin, NT1
Ozturk, K1
Cayci, Z1
Duscha, BD1
Kraus, WE1
Jones, WS1
Robbins, JL1
Piner, LW1
Huffman, KM1
Allen, JD1
Annex, BH1
Mehmood, T1
Ahmad, I1
Bibi, S1
Mustafa, B1
Ali, I1
Dahal, RH1
Chaudhary, DK1
Kim, DU1
Kim, J1
Yeter, HH1
Gonul, I1
Guz, G1
Helvaci, O1
Korucu, B1
Akcay, OF1
Derici, U1
Arinsoy, T1
Neffati, R1
Judeinstein, P1
Rault, J1
Xu, Y2
Chai, X1
Ren, T1
Yu, S1
Fu, Q2
Ye, J1
Ge, X1
Song, J1
Yang, H2
El-Baba, TJ1
Lutomski, CA1
Kantsadi, AL1
Malla, TR1
John, T1
Mikhailov, V1
Bolla, JR1
Schofield, CJ1
Zitzmann, N1
Vakonakis, I1
Robinson, CV1
Langham, MC1
Caporale, AS1
Wehrli, FW1
Parry, S1
Schwartz, N1
den Boer, RB1
Jones, KI1
Ash, S1
van Boxel, GI1
Gillies, RS1
O'Donnell, T1
Ruurda, JP1
Sgromo, B1
Silva, MA1
Maynard, ND1
Sivieri, EM1
Eichenwald, EC1
Rub, D1
Abbasi, S1
Krahnert, I1
Bolze, A1
Gibon, Y1
Fernie, AR1
Huang, L2
Wan, Y1
Dang, Z1
Yang, P1
Yang, Q1
Wu, S2
Lin, CC1
Hsu, CT1
Liu, W2
Huang, SC1
Kortz, U1
Mougharbel, AS1
Chen, TY1
Hu, CW1
Lee, JF1
Wang, CC1
Liao, YF1
Li, LJ1
Li, L2
Peng, S1
Stimming, U1
Hebbar Kannur, K1
Yaqub, TB1
Pupier, C1
Héau, C1
Cavaleiro, A1
Yamamoto, S1
Ono, A1
Matsui, J1
Hoshino, N1
Akutagawa, T1
Miyashita, T1
Mitsuishi, M1
Patel, SM1
Smith, TG1
Morton, M1
Stiers, KM1
Seravalli, J1
Mayclin, SJ1
Edwards, TE1
Tanner, JJ1
Becker, DF1
Butcher, TW1
Yang, JL1
Hartwig, JF1
Yu, MF1
Xia, ZZ1
Yao, JC1
Feng, Z1
Li, DH1
Liu, T2
Cheng, GJ1
He, DL1
Li, XH1
Huurman, R1
Schinkel, AFL1
de Jong, PL1
van Slegtenhorst, MA1
Hirsch, A1
Michels, M1
Kataja, A1
Tarvasmäki, T1
Lassus, J1
Sionis, A1
Mebazaa, A1
Pulkki, K1
Banaszewski, M1
Carubelli, V1
Hongisto, M1
Jankowska, E1
Jurkko, R1
Jäntti, T1
Kasztura, M1
Parissis, J1
Sabell, T1
Silva-Cardoso, J1
Spinar, J1
Tolppanen, H1
Harjola, VP1
Carsetti, A1
Damiani, E1
Casarotta, E1
Scorcella, C1
Domizi, R1
Gasparri, F1
Gabbanelli, V1
Pantanetti, S1
Carozza, R1
Adrario, E1
Donati, A1
Almada, E1
Pariani, A1
Rivabella Maknis, T1
Hidalgo, F1
Vena, R1
Favre, C1
Larocca, MC1
Lu, ZY1
Jiang, WD1
Wu, P1
Kuang, SY1
Tang, L1
Yang, J1
Zhou, XQ1
Feng, L1
Leal, M1
Zampini, IC1
Mercado, MI1
Moreno, MA1
Simirgiotis, MJ1
Bórquez, J1
Ponessa, G1
Isla, MI1
Saliu, IO1
Amoo, ZA1
Khan, MF1
Olaleye, MT1
Rema, V1
Akinmoladun, AC1
Khan, AU1
Rahman, AU1
Yuan, Q1
Ahmad, A1
Khan, ZUH1
Mahnashi, MH1
Alyami, BA1
Alqahtani, YS1
Ullah, S1
Wirman, AP1
Gao, M1
Deng, L1
Zhang, K1
Wang, M1
Xia, Z1
Gao, D1
Balkissou, AD1
Poka-Mayap, V1
Massongo, M1
Djenabou, A1
Endale-Mangamba, LM1
Olomo, EJ1
Boulleys-Nana, JR1
Diffo-Sonkoue, L1
Adidigue-Ndiome, R1
Alexandra, AJE1
Haman-Wabi, AB1
Adama, S1
Iddi-Faical, A1
Pefura-Yone, EW1
Zhao, Q1
Tong, W1
Ge, C1
Zhao, D1
Norbäck, D1
Li, B1
Zhao, Z1
Huang, C1
Qian, H1
Yang, X1
Sun, Y2
Sundell, J1
Deng, Q1
Kim, HJ1
Jeon, JW1
Hwang, SM1
Chu, KI1
Cha, YH1
Kwak, YD1
Choi, SD1
Aslam, M1
Kim, CG1
Yang, E1
Yang, W1
Zhu, X1
Li, Q1
Song, W1
Peng, X1
Uyar-Arpaci, P1
Zhang, L3
Dong, R1
Zhou, T1
Jia, D1
Meng, Z1
Pi, Z1
Zhuang, X1
Liu, S1
Liu, Z2
Song, F1
Abdellatef, AA1
Fathy, M1
Mohammed, AEI1
Bakr, MSA1
Ahmed, AH1
Abbass, HS1
El-Desoky, AH1
Morita, H1
Nikaido, T1
Hayakawa, Y1
Lee, D1
Park, S1
Choi, S1
Kim, SH1
Kang, KS1
Zu, C1
Qin, G1
Yang, C1
Liu, N1
He, A1
Zhang, M1
Zheng, X1
Song, Y1
Sheng, Z1
Dong, L1
Xu, W1
Li, F2
Wu, Z1
Su, Y1
Sun, X1
Ling, D1
Jelassi, B1
Anchelin, M1
Chamouton, J1
Cayuela, ML1
Clarysse, L1
Goré, J1
Jiang, LH1
Roger, S1
Li, WY1
Chan, RY1
Yu, PH1
Chan, SW1
Guo, J1
Li, W1
Shi, H1
Xie, X2
Tang, H1
Wu, M1
Kong, Y1
Yang, L1
Gao, J1
Liu, P1
Wei, W1
Sui, JQ1
Xie, KP1
Zou, W1
Xie, MJ1
Yu, F2
Iwanowycz, S2
Saaoud, F1
Hu, J1
Wang, Q1
Fan, D3
Zhou, Q1
Zhang, H1
Zhao, M1
Su, S1
Chen, B1
Ke, X1
Fu, J1
Basile, A1
Rigano, D1
Loppi, S1
Di Santi, A1
Nebbioso, A1
Sorbo, S1
Conte, B1
Paoli, L1
De Ruberto, F1
Molinari, AM1
Altucci, L1
Bontempo, P1
Tian, S1
Zhu, J1
Li, KT1
Yu, TH1
Yu, LH1
Bai, DQ1
Hodge, J1
Ma, JW1
Hung, CM1
Lin, YC1
Ho, CT1
Kao, JY1
Way, TD1
Guo, H1
Huang, Z2
Chen, G2
Shi, P2
Gupta, V1
Mun, GH1
Choi, B1
Aseh, A1
Mildred, L1
Patel, A1
Price, JE1
Chang, D1
Robb, G1
Mathur, AB2
Chen, T1
Chen, M1
Fu, JM1
Xie, JS1
Yip, AY1
Loo, WT1
Chow, LW1
Ng, EL1
Esmat, AY2
El-Gerzawy, SM1
Rafaat, A1
Tomasetto, C1
Rio, MC1
Castiglioni, F1
Tagliabue, E1
Campiglio, M1
Pupa, SM1
Balsari, A1
Ménard, S1
Cheema, SK1
Gobin, AS1
Rhea, R1
Lopez-Berestein, G1
Newman, RA1
Chang, CJ1
Bacus, SS1
Hung, MC2
Lau, YK1
Xi, L1
Hong, RL1
Kim, DS1
Chen, CF1
Hortobagyi, GN1
Chang, C1

Reviews

4 reviews available for emodin and Breast Neoplasms

ArticleYear
Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer.
    International journal of molecular sciences, 2023, Oct-31, Volume: 24, Issue:21

    Topics: Anthraquinones; Breast Neoplasms; Emodin; Female; Humans; Plant Extracts; Polygonaceae; Rheum

2023
Combination of targeted daunorubicin liposomes and targeted emodin liposomes for treatment of invasive breast cancer.
    Journal of drug targeting, 2020, Volume: 28, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Drug Delive

2020
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
P2X7 receptor: a critical regulator and potential target for breast cancer.
    Journal of molecular medicine (Berlin, Germany), 2021, Volume: 99, Issue:3

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Breast Neoplasms; Cat's Claw; Cations; Disease Progre

2021

Trials

1 trial available for emodin and Breast Neoplasms

ArticleYear
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022

Other Studies

37 other studies available for emodin and Breast Neoplasms

ArticleYear
Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
    Journal of medicinal chemistry, 2015, Jan-08, Volume: 58, Issue:1

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biologic

2015
pH-responsive and CD44-targeting polymer micelles based on CD44p-conjugated amphiphilic block copolymer PEG-
    Nanotechnology, 2022, Apr-20, Volume: 33, Issue:27

    Topics: Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Emodin; Female; Humans; Hy

2022
Peptide-Mediated Targeted Delivery of Aloe-Emodin as Anticancer Drug.
    Molecules (Basel, Switzerland), 2022, Jul-19, Volume: 27, Issue:14

    Topics: Aloe; Anthraquinones; Antineoplastic Agents; Apoptosis; Biological Products; Breast Neoplasms; Emodi

2022
Systems biology based miRNA-mRNA expression pattern analysis of Emodin in breast cancer cell lines.
    Pathology, research and practice, 2023, Volume: 249

    Topics: Breast Neoplasms; Emodin; Female; Humans; MCF-7 Cells; MicroRNAs; RNA, Messenger; Systems Biology

2023
Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription.
    Theranostics, 2020, Volume: 10, Issue:15

    Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Disease Models,

2020
Berberine and Emodin abrogates breast cancer growth and facilitates apoptosis through inactivation of SIK3-induced mTOR and Akt signaling pathway.
    Biochimica et biophysica acta. Molecular basis of disease, 2020, 11-01, Volume: 1866, Issue:11

    Topics: Apoptosis; Berberine; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Surviv

2020
Combinatorial therapy of Thymoquinone and Emodin synergistically enhances apoptosis, attenuates cell migration and reduces stemness efficiently in breast cancer.
    Biochimica et biophysica acta. General subjects, 2020, Volume: 1864, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Bre

2020
Identification of Potential Therapeutic Genes and Pathways in Phytoestrogen Emodin Treated Breast Cancer Cell Lines via Network Biology Approaches.
    Nutrition and cancer, 2022, Volume: 74, Issue:2

    Topics: Biology; Breast Neoplasms; Cell Line, Tumor; Emodin; Female; Gene Expression Regulation, Neoplastic;

2022
The anti-breast cancer property of physcion via oxidative stress-mediated mitochondrial apoptosis and immune response.
    Pharmaceutical biology, 2021, Volume: 59, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Dose-Response Relationsh

2021
The effects and mechanisms of aloe-emodin on reversing adriamycin-induced resistance of MCF-7/ADR cells.
    Phytotherapy research : PTR, 2021, Volume: 35, Issue:7

    Topics: Aloe; Breast Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Emodin; Female; Humans; MCF-7 Cells

2021
Inhibition of cell-intrinsic NF-κB activity and metastatic abilities of breast cancer by aloe-emodin and emodic-acid isolated from Asphodelus microcarpus.
    Journal of natural medicines, 2021, Volume: 75, Issue:4

    Topics: Aloe; Anthraquinones; Breast Neoplasms; Emodin; Female; Humans; NF-kappa B

2021
In Vitro Estrogenic and Breast Cancer Inhibitory Activities of Chemical Constituents Isolated from Rheum undulatum L.
    Molecules (Basel, Switzerland), 2018, May-18, Volume: 23, Issue:5

    Topics: Anthraquinones; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr

2018
Low dose Emodin induces tumor senescence for boosting breast cancer chemotherapy via silencing NRARP.
    Biochemical and biophysical research communications, 2018, 11-10, Volume: 505, Issue:4

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Cel

2018
Magnetic liposomal emodin composite with enhanced killing efficiency against breast cancer.
    Biomaterials science, 2019, Feb-26, Volume: 7, Issue:3

    Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Emodin; Female; Ferric Compounds; Hemoly

2019
Anthraquinone emodin inhibits human cancer cell invasiveness by antagonizing P2X7 receptors.
    Carcinogenesis, 2013, Volume: 34, Issue:7

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cal

2013
Emodin induces cytotoxic effect in human breast carcinoma MCF-7 cell through modulating the expression of apoptosis-related genes.
    Pharmaceutical biology, 2013, Volume: 51, Issue:9

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Carci

2013
Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a.
    Molecular and cellular biochemistry, 2013, Volume: 382, Issue:1-2

    Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Synergism; Emodin;

2013
Emodin inhibits breast cancer cell proliferation through the ERα-MAPK/Akt-cyclin D1/Bcl-2 signaling pathway.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:15

    Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cyclin D1; Emodin; E

2014
Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs.
    Breast cancer research and treatment, 2014, Volume: 148, Issue:2

    Topics: Animals; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Adhesion; Cell Movement; Cell Prolifer

2014
Inhibitory effect of emodin on migration, invasion and metastasis of human breast cancer MDA-MB-231 cells in vitro and in vivo.
    Oncology reports, 2015, Volume: 33, Issue:1

    Topics: Animals; Antineoplastic Agents; Body Weight; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Dose

2015
The anthraquinone derivative Emodin inhibits angiogenesis and metastasis through downregulating Runx2 activity in breast cancer.
    International journal of oncology, 2015, Volume: 46, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Proliferation; Core Binding Factor Alpha 1

2015
Antiproliferative, antibacterial and antifungal activity of the lichen Xanthoria parietina and its secondary metabolite parietin.
    International journal of molecular sciences, 2015, Apr-09, Volume: 16, Issue:4

    Topics: Anti-Bacterial Agents; Antifungal Agents; Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Lin

2015
Exploring a Novel Target Treatment on Breast Cancer: Aloe-emodin Mediated Photodynamic Therapy Induced Cell Apoptosis and Inhibited Cell Metastasis.
    Anti-cancer agents in medicinal chemistry, 2016, Volume: 16, Issue:6

    Topics: Aloe; Apoptosis; Breast Neoplasms; Emodin; Female; Humans; Neoplasm Metastasis; Photochemotherapy

2016
Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:8

    Topics: Animals; Biomarkers; Breast Neoplasms; Cell Communication; Cell Line, Tumor; Cell Survival; Disease

2016
Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells.
    Oncotarget, 2016, Sep-13, Volume: 7, Issue:37

    Topics: Anthraquinones; Breast Neoplasms; Carcinogenesis; Cell Movement; Down-Regulation; Emodin; Female; Gl

2016
Physcion 8-O-β-glucopyranoside suppresses the metastasis of breast cancer in vitro and in vivo by modulating DNMT1.
    Pharmacological reports : PR, 2017, Volume: 69, Issue:1

    Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Survival; DNA (Cytosine-5-)-Methyltransferase 1; D

2017
Emodin-induced apoptosis in human breast cancer BCap-37 cells through the mitochondrial signaling pathway.
    Archives of pharmacal research, 2008, Volume: 31, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cell Lin

2008
Effects of emodin on the gene expression profiling of human breast carcinoma cells.
    Cancer detection and prevention, 2009, Volume: 32, Issue:4

    Topics: Apoptosis; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cell Survival; Cells, Cultured; Emodin; Ge

2009
Repair and reconstruction of a resected tumor defect using a composite of tissue flap-nanotherapeutic-silk fibroin and chitosan scaffold.
    Annals of biomedical engineering, 2011, Volume: 39, Issue:9

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chitosan; Emodin; Female; Humans

2011
Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies.
    International journal of pharmaceutics, 2012, Jul-01, Volume: 430, Issue:1-2

    Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Ce

2012
Emodin affects ERCC1 expression in breast cancer cells.
    Journal of translational medicine, 2012, Sep-19, Volume: 10 Suppl 1

    Topics: Blotting, Western; Breast Neoplasms; Cell Survival; Cisplatin; DNA-Binding Proteins; Doxorubicin; Em

2012
DNA ploidy and S phase fraction of breast and ovarian tumor cells treated with a natural anthracycline analog (aloin).
    Cancer biology & therapy, 2005, Volume: 4, Issue:1

    Topics: Aloe; Breast Neoplasms; DNA; Emodin; Female; Humans; Ovarian Neoplasms; Ploidies; S Phase; Tumor Cel

2005
Cytotoxicity of a natural anthraquinone (Aloin) against human breast cancer cell lines with and without ErbB-2: topoisomerase IIalpha coamplification.
    Cancer biology & therapy, 2006, Volume: 5, Issue:1

    Topics: Antigens, Neoplasm; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclin B; DNA Topoisomerases, Typ

2006
Role of exon-16-deleted HER2 in breast carcinomas.
    Endocrine-related cancer, 2006, Volume: 13, Issue:1

    Topics: 3T3 Cells; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents

2006
Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
    International journal of pharmaceutics, 2007, Aug-16, Volume: 341, Issue:1-2

    Topics: Animals; Antineoplastic Agents; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Cell Proli

2007
Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.
    Cancer research, 1995, Sep-01, Volume: 55, Issue:17

    Topics: Breast Neoplasms; Cell Differentiation; Cell Division; Cell Line, Transformed; Cell Transformation,

1995
Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties.
    Oncogene, 1998, Jun-04, Volume: 16, Issue:22

    Topics: 3T3 Cells; Animals; Breast Neoplasms; Cell Division; Cell Transformation, Neoplastic; Emodin; Enzyme

1998